Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
# S2 O, u( \. \( b2 N" S: QNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
2 v7 G0 e, H8 U2 z8 c6 L: t# x+ Author Affiliations
8 d l6 L% t6 J/ L0 c/ |# @' ~/ B, {; \7 p& J" a
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
0 L1 G; }/ A# V; t2 _( i$ x; x2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan @! ^7 w0 `! {: t: m3 @% f
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
; _* Y+ r$ Y; _) f Y7 p S4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan + `, b6 d. D! C
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
9 X% U2 M; t- l7 ~8 i6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
8 K5 k/ a4 j7 t( ]7Kinki University School of Medicine, Osaka 589-8511, Japan . ?5 B3 I, W. E% _" ]
8Izumi Municipal Hospital, Osaka 594-0071, Japan ( z7 U4 x/ v6 e8 q
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan M1 I2 |- {( l# c& Y2 a* M
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
5 g/ u2 }1 D L UAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
) ~" z% U- `7 o5 P: H7 _2 N& B( @ s$ `* c2 [6 B
|